nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—UGT2B7—Epirubicin—thyroid cancer	0.298	0.461	CbGbCtD
Dabigatran etexilate—UGT1A9—Sorafenib—thyroid cancer	0.276	0.427	CbGbCtD
Dabigatran etexilate—ABCB1—Sorafenib—thyroid cancer	0.0447	0.0693	CbGbCtD
Dabigatran etexilate—ABCB1—Doxorubicin—thyroid cancer	0.0271	0.042	CbGbCtD
Dabigatran etexilate—CES1—larynx—thyroid cancer	0.0213	0.272	CbGeAlD
Dabigatran etexilate—F2—neck—thyroid cancer	0.00615	0.0786	CbGeAlD
Dabigatran etexilate—CES1—neck—thyroid cancer	0.00565	0.0722	CbGeAlD
Dabigatran etexilate—CES2—saliva-secreting gland—thyroid cancer	0.00535	0.0684	CbGeAlD
Dabigatran etexilate—NQO2—saliva-secreting gland—thyroid cancer	0.00478	0.0611	CbGeAlD
Dabigatran etexilate—CES2—trachea—thyroid cancer	0.00413	0.0527	CbGeAlD
Dabigatran etexilate—NQO2—trachea—thyroid cancer	0.00369	0.0471	CbGeAlD
Dabigatran etexilate—CES2—thyroid gland—thyroid cancer	0.00326	0.0417	CbGeAlD
Dabigatran etexilate—NQO2—thyroid gland—thyroid cancer	0.00292	0.0373	CbGeAlD
Dabigatran etexilate—CES2—head—thyroid cancer	0.0029	0.037	CbGeAlD
Dabigatran etexilate—CES1—thyroid gland—thyroid cancer	0.00269	0.0344	CbGeAlD
Dabigatran etexilate—F2—head—thyroid cancer	0.0026	0.0332	CbGeAlD
Dabigatran etexilate—NQO2—head—thyroid cancer	0.00259	0.0331	CbGeAlD
Dabigatran etexilate—CES1—head—thyroid cancer	0.00238	0.0305	CbGeAlD
Dabigatran etexilate—CES2—lymph node—thyroid cancer	0.00203	0.0259	CbGeAlD
Dabigatran etexilate—NQO2—lymph node—thyroid cancer	0.00181	0.0232	CbGeAlD
Dabigatran etexilate—CES2—Fluoropyrimidine Activity—SMUG1—thyroid cancer	0.00174	0.0833	CbGpPWpGaD
Dabigatran etexilate—CES1—lymph node—thyroid cancer	0.00167	0.0213	CbGeAlD
Dabigatran etexilate—Aspartate aminotransferase increased—Sorafenib—thyroid cancer	0.00129	0.00505	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Sorafenib—thyroid cancer	0.00128	0.00502	CcSEcCtD
Dabigatran etexilate—Malnutrition—Vandetanib—thyroid cancer	0.00128	0.00501	CcSEcCtD
Dabigatran etexilate—Gastritis—Sorafenib—thyroid cancer	0.00127	0.00496	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Sorafenib—thyroid cancer	0.00126	0.00495	CcSEcCtD
Dabigatran etexilate—Dysphagia—Sorafenib—thyroid cancer	0.00124	0.00485	CcSEcCtD
Dabigatran etexilate—Transaminases increased—Epirubicin—thyroid cancer	0.0012	0.00469	CcSEcCtD
Dabigatran etexilate—Abdominal discomfort—Sorafenib—thyroid cancer	0.00119	0.00465	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Vandetanib—thyroid cancer	0.00112	0.0044	CcSEcCtD
Dabigatran etexilate—Cough—Vandetanib—thyroid cancer	0.00112	0.00437	CcSEcCtD
Dabigatran etexilate—F2—FOXA2 and FOXA3 transcription factor networks—NKX2-1—thyroid cancer	0.00111	0.0533	CbGpPWpGaD
Dabigatran etexilate—Pneumonia—Sorafenib—thyroid cancer	0.00111	0.00435	CcSEcCtD
Dabigatran etexilate—Transaminases increased—Doxorubicin—thyroid cancer	0.00111	0.00434	CcSEcCtD
Dabigatran etexilate—Hypertension—Vandetanib—thyroid cancer	0.0011	0.00432	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Sorafenib—thyroid cancer	0.0011	0.00432	CcSEcCtD
Dabigatran etexilate—Infestation—Sorafenib—thyroid cancer	0.0011	0.00432	CcSEcCtD
Dabigatran etexilate—Arthralgia—Vandetanib—thyroid cancer	0.00109	0.00426	CcSEcCtD
Dabigatran etexilate—Chest pain—Vandetanib—thyroid cancer	0.00109	0.00426	CcSEcCtD
Dabigatran etexilate—Acute coronary syndrome—Sorafenib—thyroid cancer	0.00109	0.00426	CcSEcCtD
Dabigatran etexilate—Myocardial infarction—Sorafenib—thyroid cancer	0.00108	0.00424	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00108	0.00423	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00104	0.00409	CcSEcCtD
Dabigatran etexilate—Epistaxis—Sorafenib—thyroid cancer	0.00104	0.00408	CcSEcCtD
Dabigatran etexilate—Infection—Vandetanib—thyroid cancer	0.00104	0.00406	CcSEcCtD
Dabigatran etexilate—Thrombosis—Epirubicin—thyroid cancer	0.00103	0.00403	CcSEcCtD
Dabigatran etexilate—CES1—Fluoropyrimidine Activity—SMUG1—thyroid cancer	0.00103	0.0491	CbGpPWpGaD
Dabigatran etexilate—Nervous system disorder—Vandetanib—thyroid cancer	0.00102	0.00401	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Vandetanib—thyroid cancer	0.00102	0.004	CcSEcCtD
Dabigatran etexilate—Skin disorder—Vandetanib—thyroid cancer	0.00101	0.00397	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Sorafenib—thyroid cancer	0.000997	0.0039	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Sorafenib—thyroid cancer	0.000992	0.00388	CcSEcCtD
Dabigatran etexilate—Haemoptysis—Epirubicin—thyroid cancer	0.000986	0.00386	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Sorafenib—thyroid cancer	0.000979	0.00383	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Sorafenib—thyroid cancer	0.000974	0.00381	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Sorafenib—thyroid cancer	0.000972	0.0038	CcSEcCtD
Dabigatran etexilate—Thrombosis—Doxorubicin—thyroid cancer	0.000954	0.00373	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.000951	0.00372	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Vandetanib—thyroid cancer	0.000931	0.00364	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Sorafenib—thyroid cancer	0.00092	0.0036	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Vandetanib—thyroid cancer	0.000919	0.0036	CcSEcCtD
Dabigatran etexilate—Haemoptysis—Doxorubicin—thyroid cancer	0.000912	0.00357	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000902	0.00353	CcSEcCtD
Dabigatran etexilate—Fatigue—Vandetanib—thyroid cancer	0.0009	0.00352	CcSEcCtD
Dabigatran etexilate—Angiopathy—Sorafenib—thyroid cancer	0.0009	0.00352	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Sorafenib—thyroid cancer	0.000896	0.0035	CcSEcCtD
Dabigatran etexilate—CES2—E2F transcription factor network—CDK1—thyroid cancer	0.000894	0.0427	CbGpPWpGaD
Dabigatran etexilate—Mediastinal disorder—Sorafenib—thyroid cancer	0.000894	0.0035	CcSEcCtD
Dabigatran etexilate—Constipation—Vandetanib—thyroid cancer	0.000893	0.00349	CcSEcCtD
Dabigatran etexilate—Malnutrition—Sorafenib—thyroid cancer	0.000863	0.00338	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Vandetanib—thyroid cancer	0.000854	0.00334	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Vandetanib—thyroid cancer	0.000826	0.00323	CcSEcCtD
Dabigatran etexilate—Rectal haemorrhage—Epirubicin—thyroid cancer	0.000808	0.00316	CcSEcCtD
Dabigatran etexilate—Bone disorder—Epirubicin—thyroid cancer	0.000808	0.00316	CcSEcCtD
Dabigatran etexilate—Hyperbilirubinaemia—Epirubicin—thyroid cancer	0.000802	0.00314	CcSEcCtD
Dabigatran etexilate—Anaemia—Sorafenib—thyroid cancer	0.000798	0.00312	CcSEcCtD
Dabigatran etexilate—ABCB1—trachea—thyroid cancer	0.000796	0.0102	CbGeAlD
Dabigatran etexilate—Angioedema—Sorafenib—thyroid cancer	0.000789	0.00309	CcSEcCtD
Dabigatran etexilate—Syncope—Sorafenib—thyroid cancer	0.000774	0.00303	CcSEcCtD
Dabigatran etexilate—Blood bilirubin increased—Epirubicin—thyroid cancer	0.000771	0.00302	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Sorafenib—thyroid cancer	0.000759	0.00297	CcSEcCtD
Dabigatran etexilate—Cough—Sorafenib—thyroid cancer	0.000753	0.00295	CcSEcCtD
Dabigatran etexilate—Asthenia—Vandetanib—thyroid cancer	0.000749	0.00293	CcSEcCtD
Dabigatran etexilate—Rectal haemorrhage—Doxorubicin—thyroid cancer	0.000748	0.00293	CcSEcCtD
Dabigatran etexilate—Bone disorder—Doxorubicin—thyroid cancer	0.000748	0.00293	CcSEcCtD
Dabigatran etexilate—Hypertension—Sorafenib—thyroid cancer	0.000745	0.00292	CcSEcCtD
Dabigatran etexilate—Hyperbilirubinaemia—Doxorubicin—thyroid cancer	0.000742	0.00291	CcSEcCtD
Dabigatran etexilate—Pruritus—Vandetanib—thyroid cancer	0.000739	0.00289	CcSEcCtD
Dabigatran etexilate—Musculoskeletal pain—Epirubicin—thyroid cancer	0.000739	0.00289	CcSEcCtD
Dabigatran etexilate—Arthralgia—Sorafenib—thyroid cancer	0.000735	0.00288	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00073	0.00286	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Vandetanib—thyroid cancer	0.000715	0.0028	CcSEcCtD
Dabigatran etexilate—Blood bilirubin increased—Doxorubicin—thyroid cancer	0.000714	0.00279	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Sorafenib—thyroid cancer	0.000704	0.00276	CcSEcCtD
Dabigatran etexilate—Infection—Sorafenib—thyroid cancer	0.0007	0.00274	CcSEcCtD
Dabigatran etexilate—Shock—Sorafenib—thyroid cancer	0.000693	0.00271	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Sorafenib—thyroid cancer	0.000691	0.0027	CcSEcCtD
Dabigatran etexilate—Dizziness—Vandetanib—thyroid cancer	0.000691	0.0027	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Sorafenib—thyroid cancer	0.00069	0.0027	CcSEcCtD
Dabigatran etexilate—Skin disorder—Sorafenib—thyroid cancer	0.000684	0.00268	CcSEcCtD
Dabigatran etexilate—Musculoskeletal pain—Doxorubicin—thyroid cancer	0.000683	0.00267	CcSEcCtD
Dabigatran etexilate—Oesophagitis—Epirubicin—thyroid cancer	0.000667	0.00261	CcSEcCtD
Dabigatran etexilate—Vomiting—Vandetanib—thyroid cancer	0.000664	0.0026	CcSEcCtD
Dabigatran etexilate—Ecchymosis—Epirubicin—thyroid cancer	0.00066	0.00258	CcSEcCtD
Dabigatran etexilate—Rash—Vandetanib—thyroid cancer	0.000658	0.00258	CcSEcCtD
Dabigatran etexilate—Dermatitis—Vandetanib—thyroid cancer	0.000658	0.00257	CcSEcCtD
Dabigatran etexilate—Headache—Vandetanib—thyroid cancer	0.000654	0.00256	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000642	0.00251	CcSEcCtD
Dabigatran etexilate—ABCB1—thyroid gland—thyroid cancer	0.000629	0.00805	CbGeAlD
Dabigatran etexilate—Dyspnoea—Sorafenib—thyroid cancer	0.000628	0.00246	CcSEcCtD
Dabigatran etexilate—Nausea—Vandetanib—thyroid cancer	0.00062	0.00243	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Sorafenib—thyroid cancer	0.00062	0.00243	CcSEcCtD
Dabigatran etexilate—Oesophagitis—Doxorubicin—thyroid cancer	0.000617	0.00241	CcSEcCtD
Dabigatran etexilate—Ecchymosis—Doxorubicin—thyroid cancer	0.00061	0.00239	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000608	0.00238	CcSEcCtD
Dabigatran etexilate—Fatigue—Sorafenib—thyroid cancer	0.000607	0.00238	CcSEcCtD
Dabigatran etexilate—Hepatic function abnormal—Epirubicin—thyroid cancer	0.000606	0.00237	CcSEcCtD
Dabigatran etexilate—Constipation—Sorafenib—thyroid cancer	0.000602	0.00236	CcSEcCtD
Dabigatran etexilate—Cardiac failure congestive—Epirubicin—thyroid cancer	0.000584	0.00229	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000576	0.00225	CcSEcCtD
Dabigatran etexilate—CES2—NRF2 pathway—SLC5A5—thyroid cancer	0.000567	0.0271	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—PPAR Alpha Pathway—CDK1—thyroid cancer	0.000562	0.0268	CbGpPWpGaD
Dabigatran etexilate—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.000561	0.00219	CcSEcCtD
Dabigatran etexilate—Urticaria—Sorafenib—thyroid cancer	0.00056	0.00219	CcSEcCtD
Dabigatran etexilate—ABCB1—head—thyroid cancer	0.000558	0.00714	CbGeAlD
Dabigatran etexilate—Abdominal pain—Sorafenib—thyroid cancer	0.000557	0.00218	CcSEcCtD
Dabigatran etexilate—Cardiac failure—Epirubicin—thyroid cancer	0.000543	0.00212	CcSEcCtD
Dabigatran etexilate—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.00054	0.00211	CcSEcCtD
Dabigatran etexilate—Pain in extremity—Epirubicin—thyroid cancer	0.00053	0.00207	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.00053	0.00207	CcSEcCtD
Dabigatran etexilate—Osteoarthritis—Epirubicin—thyroid cancer	0.00053	0.00207	CcSEcCtD
Dabigatran etexilate—CES1—E2F transcription factor network—CDK1—thyroid cancer	0.000527	0.0252	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—PPAR Alpha Pathway—RXRA—thyroid cancer	0.000521	0.0249	CbGpPWpGaD
Dabigatran etexilate—Hypersensitivity—Sorafenib—thyroid cancer	0.000519	0.00203	CcSEcCtD
Dabigatran etexilate—Asthenia—Sorafenib—thyroid cancer	0.000505	0.00198	CcSEcCtD
Dabigatran etexilate—Cardiac failure—Doxorubicin—thyroid cancer	0.000502	0.00197	CcSEcCtD
Dabigatran etexilate—Pruritus—Sorafenib—thyroid cancer	0.000498	0.00195	CcSEcCtD
Dabigatran etexilate—Osteoarthritis—Doxorubicin—thyroid cancer	0.00049	0.00192	CcSEcCtD
Dabigatran etexilate—Pain in extremity—Doxorubicin—thyroid cancer	0.00049	0.00192	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.00049	0.00192	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Epirubicin—thyroid cancer	0.000489	0.00191	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Epirubicin—thyroid cancer	0.000484	0.00189	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Sorafenib—thyroid cancer	0.000482	0.00189	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metapathway biotransformation—CHST14—thyroid cancer	0.000479	0.0229	CbGpPWpGaD
Dabigatran etexilate—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000477	0.00187	CcSEcCtD
Dabigatran etexilate—CES2—NRF2 pathway—RXRA—thyroid cancer	0.000476	0.0228	CbGpPWpGaD
Dabigatran etexilate—Nasopharyngitis—Epirubicin—thyroid cancer	0.000474	0.00185	CcSEcCtD
Dabigatran etexilate—Gastritis—Epirubicin—thyroid cancer	0.000469	0.00183	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.000467	0.00183	CcSEcCtD
Dabigatran etexilate—Dizziness—Sorafenib—thyroid cancer	0.000466	0.00182	CcSEcCtD
Dabigatran etexilate—CES2—Fluoropyrimidine Activity—TP53—thyroid cancer	0.000463	0.0221	CbGpPWpGaD
Dabigatran etexilate—Influenza—Epirubicin—thyroid cancer	0.000458	0.00179	CcSEcCtD
Dabigatran etexilate—Dysphagia—Epirubicin—thyroid cancer	0.000458	0.00179	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000452	0.00177	CcSEcCtD
Dabigatran etexilate—Vomiting—Sorafenib—thyroid cancer	0.000448	0.00175	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000448	0.00175	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Epirubicin—thyroid cancer	0.000446	0.00175	CcSEcCtD
Dabigatran etexilate—Rash—Sorafenib—thyroid cancer	0.000444	0.00174	CcSEcCtD
Dabigatran etexilate—Dermatitis—Sorafenib—thyroid cancer	0.000444	0.00174	CcSEcCtD
Dabigatran etexilate—UGT1A9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000441	0.0211	CbGpPWpGaD
Dabigatran etexilate—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.000441	0.00173	CcSEcCtD
Dabigatran etexilate—Headache—Sorafenib—thyroid cancer	0.000441	0.00173	CcSEcCtD
Dabigatran etexilate—Bronchitis—Epirubicin—thyroid cancer	0.00044	0.00172	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000438	0.00171	CcSEcCtD
Dabigatran etexilate—Gastritis—Doxorubicin—thyroid cancer	0.000434	0.0017	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000432	0.00169	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000425	0.00166	CcSEcCtD
Dabigatran etexilate—Dysphagia—Doxorubicin—thyroid cancer	0.000424	0.00166	CcSEcCtD
Dabigatran etexilate—Influenza—Doxorubicin—thyroid cancer	0.000424	0.00166	CcSEcCtD
Dabigatran etexilate—Nausea—Sorafenib—thyroid cancer	0.000418	0.00164	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Doxorubicin—thyroid cancer	0.000413	0.00161	CcSEcCtD
Dabigatran etexilate—CES2—NRF2 pathway—NRG1—thyroid cancer	0.000412	0.0197	CbGpPWpGaD
Dabigatran etexilate—Pneumonia—Epirubicin—thyroid cancer	0.000411	0.00161	CcSEcCtD
Dabigatran etexilate—Infestation—Epirubicin—thyroid cancer	0.000408	0.0016	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Epirubicin—thyroid cancer	0.000408	0.0016	CcSEcCtD
Dabigatran etexilate—Bronchitis—Doxorubicin—thyroid cancer	0.000407	0.00159	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Epirubicin—thyroid cancer	0.000397	0.00155	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000394	0.00154	CcSEcCtD
Dabigatran etexilate—ABCB1—lymph node—thyroid cancer	0.000391	0.005	CbGeAlD
Dabigatran etexilate—UGT1A9—Metapathway biotransformation—CHST14—thyroid cancer	0.000389	0.0186	CbGpPWpGaD
Dabigatran etexilate—Haematuria—Epirubicin—thyroid cancer	0.000389	0.00152	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000386	0.00151	CcSEcCtD
Dabigatran etexilate—Epistaxis—Epirubicin—thyroid cancer	0.000385	0.00151	CcSEcCtD
Dabigatran etexilate—Sinusitis—Epirubicin—thyroid cancer	0.000383	0.0015	CcSEcCtD
Dabigatran etexilate—Pneumonia—Doxorubicin—thyroid cancer	0.00038	0.00149	CcSEcCtD
Dabigatran etexilate—Infestation—Doxorubicin—thyroid cancer	0.000378	0.00148	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Doxorubicin—thyroid cancer	0.000378	0.00148	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Epirubicin—thyroid cancer	0.000368	0.00144	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Doxorubicin—thyroid cancer	0.000367	0.00144	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Epirubicin—thyroid cancer	0.000366	0.00143	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Epirubicin—thyroid cancer	0.000362	0.00142	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Epirubicin—thyroid cancer	0.000361	0.00141	CcSEcCtD
Dabigatran etexilate—Haematuria—Doxorubicin—thyroid cancer	0.00036	0.00141	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Epirubicin—thyroid cancer	0.00036	0.00141	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Epirubicin—thyroid cancer	0.000359	0.00141	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000357	0.0014	CcSEcCtD
Dabigatran etexilate—Epistaxis—Doxorubicin—thyroid cancer	0.000356	0.00139	CcSEcCtD
Dabigatran etexilate—Sinusitis—Doxorubicin—thyroid cancer	0.000354	0.00139	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Doxorubicin—thyroid cancer	0.000341	0.00133	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Epirubicin—thyroid cancer	0.00034	0.00133	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Doxorubicin—thyroid cancer	0.000339	0.00133	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000335	0.00131	CcSEcCtD
Dabigatran etexilate—CES1—NRF2 pathway—SLC5A5—thyroid cancer	0.000334	0.016	CbGpPWpGaD
Dabigatran etexilate—Oedema peripheral—Doxorubicin—thyroid cancer	0.000334	0.00131	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000333	0.0013	CcSEcCtD
Dabigatran etexilate—Angiopathy—Epirubicin—thyroid cancer	0.000332	0.0013	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Doxorubicin—thyroid cancer	0.000332	0.0013	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Epirubicin—thyroid cancer	0.000331	0.0013	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Epirubicin—thyroid cancer	0.00033	0.00129	CcSEcCtD
Dabigatran etexilate—Malnutrition—Epirubicin—thyroid cancer	0.000319	0.00125	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Doxorubicin—thyroid cancer	0.000315	0.00123	CcSEcCtD
Dabigatran etexilate—Flatulence—Epirubicin—thyroid cancer	0.000314	0.00123	CcSEcCtD
Dabigatran etexilate—UGT2B15—Biological oxidations—RXRA—thyroid cancer	0.000311	0.0148	CbGpPWpGaD
Dabigatran etexilate—Back pain—Epirubicin—thyroid cancer	0.000309	0.00121	CcSEcCtD
Dabigatran etexilate—Angiopathy—Doxorubicin—thyroid cancer	0.000308	0.0012	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Doxorubicin—thyroid cancer	0.000306	0.0012	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000306	0.0012	CcSEcCtD
Dabigatran etexilate—Malnutrition—Doxorubicin—thyroid cancer	0.000295	0.00115	CcSEcCtD
Dabigatran etexilate—Anaemia—Epirubicin—thyroid cancer	0.000295	0.00115	CcSEcCtD
Dabigatran etexilate—Flatulence—Doxorubicin—thyroid cancer	0.000291	0.00114	CcSEcCtD
Dabigatran etexilate—Syncope—Epirubicin—thyroid cancer	0.000286	0.00112	CcSEcCtD
Dabigatran etexilate—Back pain—Doxorubicin—thyroid cancer	0.000286	0.00112	CcSEcCtD
Dabigatran etexilate—Palpitations—Epirubicin—thyroid cancer	0.000282	0.0011	CcSEcCtD
Dabigatran etexilate—CES1—NRF2 pathway—RXRA—thyroid cancer	0.000281	0.0134	CbGpPWpGaD
Dabigatran etexilate—Loss of consciousness—Epirubicin—thyroid cancer	0.00028	0.0011	CcSEcCtD
Dabigatran etexilate—Cough—Epirubicin—thyroid cancer	0.000278	0.00109	CcSEcCtD
Dabigatran etexilate—Hypertension—Epirubicin—thyroid cancer	0.000275	0.00108	CcSEcCtD
Dabigatran etexilate—CES1—Fluoropyrimidine Activity—TP53—thyroid cancer	0.000273	0.013	CbGpPWpGaD
Dabigatran etexilate—Anaemia—Doxorubicin—thyroid cancer	0.000273	0.00107	CcSEcCtD
Dabigatran etexilate—Arthralgia—Epirubicin—thyroid cancer	0.000272	0.00106	CcSEcCtD
Dabigatran etexilate—Chest pain—Epirubicin—thyroid cancer	0.000272	0.00106	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00027	0.00106	CcSEcCtD
Dabigatran etexilate—Syncope—Doxorubicin—thyroid cancer	0.000265	0.00104	CcSEcCtD
Dabigatran etexilate—Palpitations—Doxorubicin—thyroid cancer	0.000261	0.00102	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Epirubicin—thyroid cancer	0.00026	0.00102	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Doxorubicin—thyroid cancer	0.000259	0.00102	CcSEcCtD
Dabigatran etexilate—Infection—Epirubicin—thyroid cancer	0.000259	0.00101	CcSEcCtD
Dabigatran etexilate—Cough—Doxorubicin—thyroid cancer	0.000258	0.00101	CcSEcCtD
Dabigatran etexilate—Shock—Epirubicin—thyroid cancer	0.000256	0.001	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Epirubicin—thyroid cancer	0.000255	0.000999	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Epirubicin—thyroid cancer	0.000255	0.000997	CcSEcCtD
Dabigatran etexilate—Hypertension—Doxorubicin—thyroid cancer	0.000255	0.000997	CcSEcCtD
Dabigatran etexilate—Skin disorder—Epirubicin—thyroid cancer	0.000253	0.00099	CcSEcCtD
Dabigatran etexilate—Arthralgia—Doxorubicin—thyroid cancer	0.000251	0.000983	CcSEcCtD
Dabigatran etexilate—Chest pain—Doxorubicin—thyroid cancer	0.000251	0.000983	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.00025	0.000977	CcSEcCtD
Dabigatran etexilate—F2—GPCR ligand binding—CALCB—thyroid cancer	0.000246	0.0117	CbGpPWpGaD
Dabigatran etexilate—Hypotension—Epirubicin—thyroid cancer	0.000243	0.000952	CcSEcCtD
Dabigatran etexilate—CES1—NRF2 pathway—NRG1—thyroid cancer	0.000243	0.0116	CbGpPWpGaD
Dabigatran etexilate—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000241	0.000943	CcSEcCtD
Dabigatran etexilate—Infection—Doxorubicin—thyroid cancer	0.000239	0.000936	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000237	0.000928	CcSEcCtD
Dabigatran etexilate—Shock—Doxorubicin—thyroid cancer	0.000237	0.000927	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Doxorubicin—thyroid cancer	0.000236	0.000924	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000236	0.000923	CcSEcCtD
Dabigatran etexilate—Skin disorder—Doxorubicin—thyroid cancer	0.000234	0.000916	CcSEcCtD
Dabigatran etexilate—UGT1A9—PPAR Alpha Pathway—CCND1—thyroid cancer	0.000234	0.0112	CbGpPWpGaD
Dabigatran etexilate—Dyspnoea—Epirubicin—thyroid cancer	0.000232	0.000908	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Epirubicin—thyroid cancer	0.000229	0.000897	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—MINPP1—thyroid cancer	0.000228	0.0109	CbGpPWpGaD
Dabigatran etexilate—Hypotension—Doxorubicin—thyroid cancer	0.000225	0.000881	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000225	0.000879	CcSEcCtD
Dabigatran etexilate—Fatigue—Epirubicin—thyroid cancer	0.000224	0.000878	CcSEcCtD
Dabigatran etexilate—Constipation—Epirubicin—thyroid cancer	0.000223	0.000871	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000219	0.000859	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Doxorubicin—thyroid cancer	0.000215	0.00084	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000213	0.000833	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Doxorubicin—thyroid cancer	0.000212	0.00083	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000208	0.000814	CcSEcCtD
Dabigatran etexilate—Fatigue—Doxorubicin—thyroid cancer	0.000208	0.000813	CcSEcCtD
Dabigatran etexilate—Urticaria—Epirubicin—thyroid cancer	0.000207	0.000809	CcSEcCtD
Dabigatran etexilate—Constipation—Doxorubicin—thyroid cancer	0.000206	0.000806	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Epirubicin—thyroid cancer	0.000206	0.000805	CcSEcCtD
Dabigatran etexilate—ABCB1—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000203	0.00968	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000197	0.000771	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—NDUFA13—thyroid cancer	0.000194	0.00928	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—NRF2 pathway—SLC5A5—thyroid cancer	0.000192	0.00918	CbGpPWpGaD
Dabigatran etexilate—Hypersensitivity—Epirubicin—thyroid cancer	0.000192	0.000751	CcSEcCtD
Dabigatran etexilate—Urticaria—Doxorubicin—thyroid cancer	0.000191	0.000749	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Doxorubicin—thyroid cancer	0.00019	0.000745	CcSEcCtD
Dabigatran etexilate—Asthenia—Epirubicin—thyroid cancer	0.000187	0.000731	CcSEcCtD
Dabigatran etexilate—Pruritus—Epirubicin—thyroid cancer	0.000184	0.000721	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—CHST14—thyroid cancer	0.000182	0.00872	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—CP—thyroid cancer	0.00018	0.00863	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—EPO—thyroid cancer	0.00018	0.00859	CbGpPWpGaD
Dabigatran etexilate—Diarrhoea—Epirubicin—thyroid cancer	0.000178	0.000697	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Doxorubicin—thyroid cancer	0.000177	0.000694	CcSEcCtD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—SST—thyroid cancer	0.000173	0.00828	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Doxorubicin—thyroid cancer	0.000173	0.000676	CcSEcCtD
Dabigatran etexilate—Dizziness—Epirubicin—thyroid cancer	0.000172	0.000674	CcSEcCtD
Dabigatran etexilate—Pruritus—Doxorubicin—thyroid cancer	0.00017	0.000667	CcSEcCtD
Dabigatran etexilate—Vomiting—Epirubicin—thyroid cancer	0.000166	0.000648	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Doxorubicin—thyroid cancer	0.000165	0.000645	CcSEcCtD
Dabigatran etexilate—UGT1A9—PPARA activates gene expression—RXRA—thyroid cancer	0.000164	0.00786	CbGpPWpGaD
Dabigatran etexilate—Rash—Epirubicin—thyroid cancer	0.000164	0.000642	CcSEcCtD
Dabigatran etexilate—Dermatitis—Epirubicin—thyroid cancer	0.000164	0.000642	CcSEcCtD
Dabigatran etexilate—Headache—Epirubicin—thyroid cancer	0.000163	0.000638	CcSEcCtD
Dabigatran etexilate—UGT2B7—NRF2 pathway—RXRA—thyroid cancer	0.000161	0.00771	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—RXRA—thyroid cancer	0.000161	0.00769	CbGpPWpGaD
Dabigatran etexilate—Dizziness—Doxorubicin—thyroid cancer	0.000159	0.000623	CcSEcCtD
Dabigatran etexilate—UGT1A9—NRF2 pathway—SLC5A5—thyroid cancer	0.000156	0.00746	CbGpPWpGaD
Dabigatran etexilate—Nausea—Epirubicin—thyroid cancer	0.000155	0.000605	CcSEcCtD
Dabigatran etexilate—Vomiting—Doxorubicin—thyroid cancer	0.000153	0.000599	CcSEcCtD
Dabigatran etexilate—Rash—Doxorubicin—thyroid cancer	0.000152	0.000594	CcSEcCtD
Dabigatran etexilate—Dermatitis—Doxorubicin—thyroid cancer	0.000152	0.000594	CcSEcCtD
Dabigatran etexilate—Headache—Doxorubicin—thyroid cancer	0.000151	0.000591	CcSEcCtD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000149	0.00714	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—HPGD—thyroid cancer	0.000147	0.00703	CbGpPWpGaD
Dabigatran etexilate—Nausea—Doxorubicin—thyroid cancer	0.000143	0.00056	CcSEcCtD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—EPO—thyroid cancer	0.000142	0.00677	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Biological oxidations—RXRA—thyroid cancer	0.000141	0.00676	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—NRF2 pathway—NRG1—thyroid cancer	0.000139	0.00667	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CALCB—thyroid cancer	0.000139	0.00664	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.000137	0.00654	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—NRF2 pathway—RXRA—thyroid cancer	0.000131	0.00627	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet Aggregation (Plug Formation)—AKT1—thyroid cancer	0.000129	0.00619	CbGpPWpGaD
Dabigatran etexilate—F2—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.000129	0.00616	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CALCB—thyroid cancer	0.000126	0.00603	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000122	0.00584	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000122	0.00582	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000116	0.00555	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Biological oxidations—RXRA—thyroid cancer	0.000115	0.0055	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—TSHR—thyroid cancer	0.000114	0.00544	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—NRF2 pathway—NRG1—thyroid cancer	0.000113	0.00542	CbGpPWpGaD
Dabigatran etexilate—F2—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	0.000113	0.00539	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—thyroid cancer	0.000111	0.0053	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—BRAF—thyroid cancer	0.000105	0.005	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—MINPP1—thyroid cancer	0.000104	0.00497	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—PPARA activates gene expression—PPARG—thyroid cancer	0.000104	0.00496	CbGpPWpGaD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—AKT1—thyroid cancer	0.000102	0.00486	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—thyroid cancer	0.000102	0.00486	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PRKAR1A—thyroid cancer	0.0001	0.00478	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—PTCH1—thyroid cancer	9.67e-05	0.00462	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—TP53—thyroid cancer	9.65e-05	0.00461	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—NRAS—thyroid cancer	9.12e-05	0.00436	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—SST—thyroid cancer	8.85e-05	0.00423	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—NDUFA13—thyroid cancer	8.84e-05	0.00422	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—TERT—thyroid cancer	8.81e-05	0.00421	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CALCA—thyroid cancer	8.52e-05	0.00407	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—TPR—thyroid cancer	8.45e-05	0.00404	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—MINPP1—thyroid cancer	8.45e-05	0.00404	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	8.43e-05	0.00403	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CHST14—thyroid cancer	8.31e-05	0.00397	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PRKAR1A—thyroid cancer	8.31e-05	0.00397	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—KRAS—thyroid cancer	7.85e-05	0.00375	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CALCB—thyroid cancer	7.45e-05	0.00356	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—NDUFA13—thyroid cancer	7.18e-05	0.00343	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TRIM33—thyroid cancer	7.06e-05	0.00338	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	7e-05	0.00335	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CHST14—thyroid cancer	6.75e-05	0.00323	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—HPGD—thyroid cancer	6.7e-05	0.0032	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—HRAS—thyroid cancer	6.67e-05	0.00319	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—IFNA2—thyroid cancer	6.63e-05	0.00317	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—NRAS—thyroid cancer	6.58e-05	0.00314	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—TSHR—thyroid cancer	6.43e-05	0.00307	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—SLC5A5—thyroid cancer	6.32e-05	0.00302	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—TSHR—thyroid cancer	5.84e-05	0.00279	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PRKAR1A—thyroid cancer	5.74e-05	0.00275	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—KRAS—thyroid cancer	5.66e-05	0.00271	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—HPGD—thyroid cancer	5.44e-05	0.0026	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—RXRA—thyroid cancer	5.31e-05	0.00254	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—SST—thyroid cancer	5e-05	0.00239	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PTCH1—thyroid cancer	4.96e-05	0.00237	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	4.9e-05	0.00234	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	4.85e-05	0.00232	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CALCA—thyroid cancer	4.81e-05	0.0023	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TCF7L1—thyroid cancer	4.71e-05	0.00225	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—SST—thyroid cancer	4.54e-05	0.00217	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.41e-05	0.00211	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CALCA—thyroid cancer	4.37e-05	0.00209	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	4.22e-05	0.00202	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CDK1—thyroid cancer	3.96e-05	0.00189	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—MINPP1—thyroid cancer	3.87e-05	0.00185	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—TPR—thyroid cancer	3.85e-05	0.00184	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PRKAR1A—thyroid cancer	3.78e-05	0.00181	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	3.59e-05	0.00172	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TSHR—thyroid cancer	3.45e-05	0.00165	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PRKAR1A—thyroid cancer	3.39e-05	0.00162	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PPARG—thyroid cancer	3.35e-05	0.0016	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NDUFA13—thyroid cancer	3.29e-05	0.00157	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MEN1—thyroid cancer	3.24e-05	0.00155	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—TPR—thyroid cancer	3.13e-05	0.00149	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	3.1e-05	0.00148	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CHST14—thyroid cancer	3.1e-05	0.00148	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PRKAR1A—thyroid cancer	3.08e-05	0.00147	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	3.06e-05	0.00146	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	3.06e-05	0.00146	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	3.01e-05	0.00144	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTCH1—thyroid cancer	2.93e-05	0.0014	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—SLC5A5—thyroid cancer	2.88e-05	0.00138	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	2.83e-05	0.00135	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.79e-05	0.00133	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SST—thyroid cancer	2.68e-05	0.00128	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PTGS2—thyroid cancer	2.64e-05	0.00126	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CALCA—thyroid cancer	2.58e-05	0.00123	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—HPGD—thyroid cancer	2.5e-05	0.00119	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—NRAS—thyroid cancer	2.47e-05	0.00118	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—RXRA—thyroid cancer	2.42e-05	0.00116	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	2.41e-05	0.00115	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—SLC5A5—thyroid cancer	2.34e-05	0.00112	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CDK1—thyroid cancer	2.34e-05	0.00112	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PTEN—thyroid cancer	2.3e-05	0.0011	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	2.29e-05	0.0011	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.19e-05	0.00105	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	2.18e-05	0.00104	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—KRAS—thyroid cancer	2.13e-05	0.00102	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	2.1e-05	0.001	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—RXRA—thyroid cancer	1.97e-05	0.00094	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	1.93e-05	0.000921	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.91e-05	0.000914	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TP53—thyroid cancer	1.89e-05	0.000904	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NRG1—thyroid cancer	1.88e-05	0.000897	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—HRAS—thyroid cancer	1.81e-05	0.000865	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TERT—thyroid cancer	1.68e-05	0.000805	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	1.61e-05	0.000771	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HIF1A—thyroid cancer	1.61e-05	0.00077	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—AKT1—thyroid cancer	1.6e-05	0.000764	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PPARG—thyroid cancer	1.53e-05	0.00073	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—TPR—thyroid cancer	1.43e-05	0.000685	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	1.43e-05	0.000685	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—NRAS—thyroid cancer	1.42e-05	0.000678	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PRKAR1A—thyroid cancer	1.41e-05	0.000674	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—BRAF—thyroid cancer	1.33e-05	0.000638	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—AKT1—thyroid cancer	1.33e-05	0.000634	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PPARG—thyroid cancer	1.24e-05	0.000593	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—KRAS—thyroid cancer	1.22e-05	0.000584	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.21e-05	0.000579	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTGS2—thyroid cancer	1.2e-05	0.000574	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SLC5A5—thyroid cancer	1.07e-05	0.000513	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTEN—thyroid cancer	1.05e-05	0.000501	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—HRAS—thyroid cancer	1.04e-05	0.000496	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—AKT1—thyroid cancer	1.01e-05	0.000483	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTGS2—thyroid cancer	9.77e-06	0.000467	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCND1—thyroid cancer	9.73e-06	0.000465	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTEN—thyroid cancer	9.4e-06	0.000449	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—AKT1—thyroid cancer	9.17e-06	0.000438	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—RXRA—thyroid cancer	9.02e-06	0.000431	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTEN—thyroid cancer	8.52e-06	0.000407	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NRAS—thyroid cancer	8.38e-06	0.000401	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KRAS—thyroid cancer	7.22e-06	0.000345	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TP53—thyroid cancer	6.41e-06	0.000307	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HRAS—thyroid cancer	6.13e-06	0.000293	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—AKT1—thyroid cancer	6.04e-06	0.000289	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PPARG—thyroid cancer	5.69e-06	0.000272	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AKT1—thyroid cancer	5.42e-06	0.000259	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—AKT1—thyroid cancer	4.91e-06	0.000235	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTGS2—thyroid cancer	4.48e-06	0.000214	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTEN—thyroid cancer	3.91e-06	0.000187	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—AKT1—thyroid cancer	2.25e-06	0.000108	CbGpPWpGaD
